This study aimed to evaluate choroidal thickness (CT) and choroidal vascularity index (CVI) in patients with Graves’ disease (GD) without ocular involvement.
Methods:
Fifty patients diagnosed with GD and 50 age and gender matched healthy control subjects were retrospectively evaluated. Measurements were taken from five different points on CT images. Choroid images were classified as lumen regions (LA) and stromal regions (SA) using the image binarization method. CVI was calculated by dividing LA by the total choroidal area (TCA). The effects of Thyrotropin Receptor Antibody (TRAb), age, GD duration, blood pressure, axial length measurements, and intraocular pressure were analyzed on CT and CVI measurements.
Results:
Mean age was 40.1 ± 13.5 years in the patient group and 39.3 ± 13.6 years in the control group (p = 0.89). There was no significant difference between the GD group and control group in terms of CT measurements. There was a significant difference between the mean CVI measurements of the GD group and control group (68.03 ± 3.41 and 66.62 ± 3.11, respectively) (p < 0.001). Univariate linear regression analysis revealed a positive correlation between TRAb and CVI (p = 0.013).
Conclusion:
While there was no significant difference between the CT measurements of the GD group and the control group, the GD group had significantly higher CVI measurements.
MichalekKMorshedSALatifR, et al. TSH receptor autoantibodies. Autoimmun Rev2009; 9(2): 113–116.
5.
CappelliCPirolaIDe MartinoE, et al. The role of imaging in Graves’ disease: a cost-effectiveness analysis. Eur J Radiol2008; 65(1): 99–103.
6.
FarghalyH. Role of radioactive iodine uptake in management of thyroid disease. J Nucl Med2012; 53(Suppl. 1): 1025.
7.
BartleyGBFatourechiVKadrmasEF, et al. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol1996; 121(3): 284–290.
8.
NicklaDLWallmanJ. The multifunctional choroid. Prog Retin Eye Res2010; 29(2): 144–168.
9.
ArakiMTakahashiH. Observations on the corrosion casts of the retinal capillary bed at the posterior pole and the capillaries of the optic disc: normal and glaucomatous eye (author’s transl). Nippon Ganka Gakkai Zasshi1977; 81(8): 982–994.
10.
BoonarphaNZhengYStangosAN, et al. Standardization of choroidal thickness measurements using enhanced depth imaging optical coherence tomography. Int J Ophthalmol2015; 8(3): 484–491.
11.
AgrawalRGuptaPTanKA, et al. Choroidal vascularity index as a measure of vascular status of the choroid: measurements in healthy eyes from a population-based study. Sci Rep2016; 6: 21090.
12.
ChhablaniJWongIYKozakI. Choroidal imaging: a review. Saudi J Ophthalmol2014; 28(2): 123–128.
13.
SanderBPCollinsMJReadSA. The effect of topical adrenergic and anticholinergic agents on the choroidal thickness of young healthy adults. Exp Eye Res2014; 128: 181–189.
14.
CaliskanSAcarMGurdalC. Choroidal thickness in patients with Graves’ ophthalmopathy. Curr Eye Res2017; 42(3): 484–490.
15.
YildirimGSahliEAlpMN. Evaluation of the effect of proptosis on choroidal thickness in Graves’ ophthalmopathy. Turk J Ophthalmol2020; 50(4): 221–227.
16.
YuNZhangYKangL, et al. Analysis in choroidal thickness in patients with Graves’ ophthalmopathy using spectral-domain optical coherence tomography. J Ophthalmol2018; 2018: 3529395.
17.
BartleyGBGormanCA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol1995; 119(6): 792–795.
18.
LaiFHPIaoTWUNgDSC, et al. Choroidal thickness in thyroid-associated orbitopathy. Clin Exp Ophthalmol2019; 47(7): 918–924.
19.
KimJYoonSBaekS. Increase of central foveal and temporal choroidal thickness in patients with inactive thyroid eye disease. BMC Ophthalmol2021; 21(1): 32.
20.
GulABasuralEOzturkHE. Comparison of choroidal thickness in patients with active and stable thyroid eye disease. Arq Bras Oftalmol2019; 82(2): 124–128.
21.
MargolisRSpaideRF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol2009; 147(5): 811–815.
22.
OotoSHangaiMYoshimuraN. Effects of sex and age on the normal retinal and choroidal structures on optical coherence tomography. Curr Eye Res2015; 40(2): 213–225.
23.
AksoyMSimsekMApaydinM. Choroidal vascularity index in patients with type-1 diabetes mellitus without diabetic retinopathy. Curr Eye Res2021; 46(6): 865–870.
24.
MenconiFOppenheimYLTomerY. Graves disease. In: ShoenfeldYCerveraRGershwinME (eds) Diagnostic criteria in autoimmune diseases. Totowa, NJ: Humana Press, 2008, pp.231–235.
25.
CappelliCGandossiECastellanoM, et al. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocr J2007; 54(5): 713–720.
26.
WiersingaWM. Autoimmunity in Graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?J Clin Endocrinol Metab2011; 96(8): 2386–2394.
27.
VitaRDi BariFPerelliS, et al. Thyroid vascularization is an important ultrasonographic parameter in untreated Graves’ disease patients. J Clin Transl Endocrinol2019; 15: 65–69.
28.
BogazziFBartalenaLBrogioniS, et al. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography. Eur J Endocrinol1999; 140(5): 452–456.
29.
ShihSRChangJSLinLC, et al. The relationship between thyrotropin receptor antibody levels and intrathyroid vascularity in patients with Graves’ disease. Exp Clin Endocrinol Diabetes2013; 121(1): 1–5.
30.
Ramos-LeviAMMarazuelaM. Pathogenesis of thyroid autoimmune disease: the role of cellular mechanisms. Endocrinol Nutr2016; 63(8): 421–429.
31.
KajdaniukDMarekBNiedziolka-ZielonkaD, et al. Transforming growth factor β1 (TGFβ1) and vascular endothelial growth factor (VEGF) in the blood of healthy people and patients with Graves’ orbitopathy—a new mechanism of glucocorticoids action?Endokrynol Pol2014; 65(5): 348–356.
32.
TurnerHEHarrisALMelmedS, et al. Angiogenesis in endocrine tumors. Endocr Rev2003; 24(5): 600–632.
33.
BaldiniMCastagnoneDRivoltaR, et al. Thyroid vascularization by color doppler ultrasonography in Graves’ disease. Changes related to different phases and to the long-term outcome of the disease. Thyroid1997; 7(6): 823–828.
34.
Del NoceCVaggeANicoloM, et al. Evaluation of choroidal thickness and choroidal vascular blood flow in patients with thyroid-associated orbitopathy (TAO) using SD-OCT and Angio-OCT. Graefes Arch Clin Exp Ophthalmol2020; 258(5): 1103–1107.
35.
GedizBSDoguiziSOzenO, et al. Is choroidal vascularity index a useful marker in different stages of idiopathic epiretinal membranes?Photodiagnosis Photodyn Ther2021; 33: 102110.
36.
BangaJPMoshkelgoshaSBerchner-PfannschmidtU, et al. Modeling Graves’ orbitopathy in experimental Graves’ disease. Horm Metab Res2015; 47(10): 797–803.
